Although the small number of patients evaluated for the coexpression of IGF1R and E‐cadherin precludes firm conclusions to be drawn, the reduction in IGF1R(+)/E‐cadherin(+) CTC counts in parallel with the increase in IGF1R(−)/E‐cadherin(−) CTCs on disease progression suggests that IGF1R may preserve a less aggressive disease phenotype in breast cancer through the interaction with E‐cadherin. The gene discussed is IGF1R; the disease is breast carcinoma.